BioSpace News Archive

Acurx Pharmaceuticals, Inc. today announced that one scientific oral presentation and one scientific poster highlighting new information about its lead antibiotic ibezapolstat relating to its selectivity against Gram-positive gut microbiota was presented on October 20, 2022 at the Infectious Disease Society of America (IDSA) IDWeek™ 2022 Conference held October 19-23, 2022 in Washington, DC.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that an oral presentation highlighting clinical data from the Phase 3 INVIGORATE allergen chamber trial of reproxalap in allergic conjunctivitis will be presented at the American Academy of Optometry 2022 Annual Meeting, taking place in San Diego October 26-29, 2022.

Orionis Biosciences today will present preclinical data supporting its Allo-GlueTM protein degradation platform for discovery and rational design of small molecule molecular glues at the 5th Annual Targeted Protein Degradation Summit, taking place October 25 – 28 in Boston.

Radiopharm Theranostics and NorthStar Medical Radioisotopes, LLC today announced they have entered into a clinical supply agreement.

Nimbus Therapeutics today announced the appointment of Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from two analyses of the UPLIZNA Phase 3 pivotal trial being presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2022), Oct. 26-28 in Amsterdam.

Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium.

Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI ™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.

Pieris Pharmaceuticals, Inc. today announced that it will host a third quarter 2022 investor call on Wednesday, November 2, 2022 at 8:00 AM EDT to discuss financial results and provide a corporate update.

INmune Bio, Inc. today announced that it will host a conference call on Wednesday, November 2, 2022 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2022.